The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.
 
Jaume Mora
No Relationships to Disclose
 
Brian H. Kushner
No Relationships to Disclose
 
Miguel Angel Flores
No Relationships to Disclose
 
Vicente Santa-María
No Relationships to Disclose
 
Moira Garraus
No Relationships to Disclose
 
Ellen M. Basu
No Relationships to Disclose
 
Stephen S. Roberts
Research Funding - Syros Pharmaceuticals (Inst)
 
Alicia Castañeda
No Relationships to Disclose
 
Maite Gorostegui
No Relationships to Disclose
 
Nai-Kong V. Cheung
Stock and Other Ownership Interests - Ymabs Therapeutics Inc
Consulting or Advisory Role - AstraZeneca/MedImmune
Research Funding - Ymabs Therapeutics Inc (Inst)
Patents, Royalties, Other Intellectual Property - affinity matured hu8H9 (Inst); anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof (Inst); anti-GD2 antibodies (Inst); bispecific HER2 and CD3 binding molecules (Inst); GD2 peptide mimics (Inst); generation and use of HLA-A2–restricted peptide-specific mAbs and CARs (Inst); high-affinity anti-GD2 antibodies (Inst); methods for detecting MRD (Inst); methods for preparing and using scFv (Inst); multimerization technologies (Inst); ROR2 antibodies (Inst); scfv constructs of anti-GD2 antibodies (Inst); therapy-enhancing glucan (Inst); use of mAb 8H9 (Inst)
 
Shakeel Modak
Consulting or Advisory Role - Ymabs Therapeutics Inc